2020 |
Kathrin Sugg |
Assessment of the Quality Part of a Finished Product Dossier of old products - Typical gaps, possible root causes, consequences of gaps *** |
|
|
2020 |
Anna von Medem |
Vor- und Nachteile der europäischen Implementierung über SPOR anhand des Anwendungsbeispiels der eSubmission *** |
|
|
2020 |
Dr. Felicitas Wendling |
Regulatory Considerations regarding Multilingual Labelling in the EU |
|
|
2020 |
Dr. Hilke Zander |
Regulatory requirements for histology independent indications in oncology *** |
|
|
2019 |
Kristina Baitinger |
Application for Marketing Authorisation for a Generic Medicinal Product in Germany and Canada - Comparative presentation of content in Module 3 considering the country specific Regulatory Requirements |
|
|
2019 |
Dr. Alexandra Baumann |
The obese patient - regulatory framework and challenges for the development, approval and prescription of medicinal products used in overweight subjects with a focus on the European Union *** |
|
|
2019 |
Dr. Veronika Bernek |
New challenges for medical device manufacturers: Implementation opportunities for post-market surveillance regarding the new MDR 745/2017 requirements for medical devices |
|
|
2019 |
Andrea Brischle |
Voluntary post-authorisation studies: differentiation, regulatory requirements and value *** |
|
|
2019 |
Lena Chugunow |
Innovative Immunotherapy in Oncology - PD-1 / PD-L1 Inhibitors in Treatment of Non-Small Cell Lung Cancer (NSCLC) and its Regulatory Aspects |
|
|
2019 |
Genoveva Dimitrova |
Direct Healthcare Professional Communication (DHPC) als Teil der Risikokommunikation resultierend aus europäischen Verfahren und ihre nationale Umsetzung in Deutschland |
|
|
2019 |
Dr. Abdelouahid El-Khattouti |
Generic Drugs: eCTD module 3 differences and similarities between US and Europe with a special focus on IV-drugs |
|
|
2019 |
Dr. Anna Ernst |
The Nagoya Protocol - Background and impact on Pharmaceutical Industry *** |
|
|
2019 |
Iris Fichert |
Today's regulatory strategies and clinical approaches for the development of treatment regimens for active MDR-TB |
|
|
2019 |
Dr. Ornella Fumagalli |
Regulatory requirements for CAR-T Cell Therapy against cancer - a comparison between the EU and the US *** |
|
|
2019 |
Moritz Hass |
The new aspects and changes of the Medical Device Regulation on classification of Medical devices with focus on software |
|
|
2019 |
Nicole Hauptmann |
Interchangeability of biosimilars - comparison of EU and US perspective *** |
|
|
2019 |
Mireille Hertel |
Mergers & Acquisitions - European Regulatory Affairs challenges to achieve a portfolio harmonization - a company perspective *** |
|
|
2019 |
Dr. Bastian Hoffmann |
In the Area of Tension between the Conditional Marketing Authorization and the Health Technology Assessment: Challenges for the Pharmaceutical Industry |
|
|
2019 |
Dr. Katharina Holl |
BCS-based biowaivers in the context of ICH M9 and its implications on the pharmaceutical industry *** |
|
|
2019 |
Tobias Hyneck |
Verschreibung und Abgabe von Betäubungsmitteln in Deutschland, Österreich und der Schweiz *** |
|
|